JaypeeDigital

Speciality

TESTIMONIALS

NEWSLETTERS

Subscribe to be the first to know about Best Deals and Exclusive Offers!

EXPORT CITATION

Chapter-002 Antiplatelets and Antithrombotics after DES: What Next?

BOOK TITLE: CSI: Cardiology Update 2014

Author
1. Kaul Upendra
2. Arora Parneesh
ISBN
9789351526186
DOI
10.5005/jp/books/12415_3
Edition
1/e
Publishing Year
2015
Pages
5
Author Affiliations
1. Batra Hospital and Medical Research Centre, 1, Tughlakabad Institutional Area, Mehrauli-Badarpur Road, New Delhi, Batra Hospital and Medical Research Center, New Delhi; Jamia Hamdard University and Amity University, Noida, Uttar Pradesh, India, Academics and Research, Batra Heart Center and Batra Hospital, and Medical Research Center, New Delhi, India, Academics and Research, Batra Hospital and Medical Research Center, New Delhi, India, Batra Heart Center and Batra Hospital and Medical Research Center, New Delhi, India, Batra Hospital and Medical Research Center, New Delhi, India, Batra Heart Centre, Batra Hospital and Medical Research Centre, New Delhi, India, Clinical Research, Fortis Healthcare, New Delhi, India, Fortis Escorts Heart, Institute and Research Centre, Vasant Kunj, New Delhi, India; National CSI, Fortis Health Care, New Delhi, India, Fortis Escorts Heart Institute and Fortis Hospital, New Delhi, India, Fortis Escorts Heart Institute and Research Center, New Delhi, India, Fortis Escorts Heart I
2. Fortis Hospital, Noida, Uttar Pradesh, India, Max Super Speciality Hospital, Patparganj, New Delhi, India
Chapter keywords
Antiplatelets, antithrombotics, percutaneous, therapeutic, cardiovascular, Cangrelor, Antithrombotic Agents, Thrombin, Dual antiplatelet therapy, tailored antiplatelet therapy

Abstract

The present chapter emphasis on antiplatelets and antithrombotics after DES. Addition of a P2Y12 adenosine diphosphate (ADP) receptor inhibitor to aspirin [acetylsalicylic acid (ASA)] or dual antiplatelet therapy (DAPT) is the current standard of care for the secondary prevention of cardiovascular (CV) death and events after percutaneous coronary intervention. In spite of all benefits, there are issues related to narrow therapeutic window, limited efficacy, drug resistance, optimal dosing, and safety. The chapter also mentions shows currently available P2Y12-receptor antagonists such as Cangrelor, Elinogrel, Thrombin and it also highlights on Properties of current and emerging P2Y12 adenosine diphosphate (ADP) receptor antagonists. Newer novel antiplatelet agents, TAPT and newer antithrombotic drug regimens in combination with antiplatelets, are being evaluated which has reduced the risk of bleeding. The introduction of the tailored therapy must be improved for the better outcome.

Related Books

3988 eBooks
11920 Videos
80651 MCQs
91 eJournals

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved